No Proof Of Added Benefit Found For Aflibercept In Wet Age-Related Macular Degeneration

Manufacturer's dossier did not contain any usable data for the comparison with ranibizumab The drug aflibercept (trade name: Eylea) has been approved in Germany since November 2012 for the treatment of wet age-related macular degeneration (AMD)...

Full Story →